Kornimate/medical-research-clean huggingface dataset:
radicle relief 2: a study of health and wellness products on pain and health outcomes

Conditions: Pain; Neuropathic Pain; Nociceptive Pain

Summary: a randomized, blinded, placebo-controlled study assessing the impact of health and wellness products on pain and other health outcomes

this is a randomized, blinded, placebo-controlled study conducted with adult participants, age 21 and older and residing in the united states. eligible participants will (1) endorse a desire for less pain, (2) indicate an interest in taking a health and wellness product to potentially help their pain, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study. participants with known liver or kidney disease, heavy drinkers, and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. those taking certain medications will be excluded. self-reported data are collected electronically from eligible participants over 7 weeks. participant reports of health indicators will be collected during baseline, throughout the active period of study product use, and in a final survey. all study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.

Eligibility criteria:
inclusion criteria: * adults, 21 years of age and older at the time of electronic consent, inclusive of all ethnicities, races, genders and/or gender identities * resides in the united states * endorses less pain as a primary desire * selects pain and/or looking to improve their pain as a reason for their interest in taking a health and wellness product * expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study exclusion criteria: * reports being pregnant, trying to become pregnant, or breastfeeding * unable to provide a valid us shipping address and mobile phone number * the calculated validated health survey (pro) score during enrollment represents less than mild severity * reports a diagnosis of liver or kidney disease * reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day) * unable to read and understand english * reports current enrollment in a clinical trial * lack of reliable daily access to the internet * reports current or recent (within 3 months) use of chemotherapy or immunotherapy * reports taking medications with a known moderate or severe interaction with any of the active ingredients studied, or a substantial safety risk: anticoagulants, a medication that warns against grapefruit consumption, corticosteroids at doses greater than 5 mgs per day, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, or maois (monoamine oxidase inhibitors) * reports a diagnosis of heart disease when a known contraindication exists for any of the active ingredients studied: nyha (new york heart association) class iii or iv congestive heart failure, atrial fibrillation, uncontrolled arrhythmias
phase 2 efficacy study of primaquine and methylene blue

Conditions: Malaria

Summary: the purpose of this study is to determine the most efficacious transmission blocking drug regimen for seasonal malaria chemoprophylaxis in mali. the primary outcome measure will be the proportion of mosquitoes infected pre and post-treatment, assessed through membrane feeding and measured by oocyst prevalence in mosquitoes dissected on day 7 post feed. primary endpoint will be a within group comparison between the mean of the pretreatment infectivity (day 0) and infectivity at 7 days post first dose.

protocol will be shared on request.

Eligibility criteria:
inclusion criteria: * glucose-6-phosphate dehydrogenase (g6pd) normal defined by carestart™ g6pd rapid diagnostic test (rdt) or the osmmr2000 g6pd semi-qualitative test * absence of symptomatic falciparum malaria, defined by fever upon enrollment * presence of p. falciparum gametocytes on thick blood film at a density \>30 gametocytes/µl (i.e. ≥2 gametocytes recorded in the thick film against 500 white blood cells) * no allergies to study drugs * no self-reported use of antimalarial drugs over the past 7 days (as reported by the participant) * hemoglobin ≥ 10 g/dl * individuals weighing \<80 kg * no evidence of severe or chronic disease * written, informed consent exclusion criteria: * age \ 50 years * female gender * blood thick film negative for sexual stages of malaria * previous reaction to study drugs/known allergy to study drugs * signs of severe malaria, including hyperparasitemia, defined as asexual parasitemia \> 100,000 parasites / µl) * signs of acute or chronic illness, including hepatitis * use of other medications (with the exception of paracetamol and/or aspirin) * consent not given
a trial of point of care information in ambulatory pediatrics

Conditions: Acute Otitis Media; Allergic Rhinitis; Sinusitis; Constipation; Pharyngitis; Croup; Urticaria; Bronchiolitis

Summary: does presentation of clinical evidence for decision making at point-of-care improve prescribing patterns in ambulatory pediatrics?

we showed previously that an electronic prescription writer and decision support system improved pediatric prescribing behavior for otitis media in an academic clinic setting. this study assessed whether point-of-care evidence delivery could demonstrate similar effects for a wide range of other common pediatric conditions. we performed a randomized controlled trial in a teaching clinic/clinical practice site and a primary care pediatric clinic serving a rural and semi-urban patient mix. there were 36 providers at the teaching clinic/practice site, and 8 providers at the private primary pediatric clinic, and an evidence-based message system presented real time evidence to providers based on prescribing practices for acute otitis media, allergic rhinitis, sinusitis, constipation, pharyngitis, croup, urticaria, and bronchiolitis. we measured the proportion of prescriptions dispensed in accordance with evidence.

Eligibility criteria:
inclusion criteria: the 44 clinical providers at the two participating clinics. - exclusion criteria: study investigators -

Keywords: point of care evidence based medicine
a study of mk-3655 in individuals with pre-cirrhotic nonalcoholic steatohepatitis (nash) (mk-3655-001)

Conditions: Nonalcoholic Steatohepatitis

Summary: this study will evaluate the effect of each dose of mk-3655 versus placebo on the percentage of individuals with nash resolution without worsening of fibrosis after 52 weeks. the primary hypothesis of the study is that at least 1 dose of mk-3655 is superior to placebo with respect to the percentage of individuals with nash resolution without worsening of fibrosis after 52 weeks.


Eligibility criteria:
inclusion criteria: * has histological confirmation of nash * is a male or female aged 18 years to 80 years (in japan and taiwan aged 20 to 80 years) * has a body mass index (bmi) ≥25 kg/m\^2 and ≤50 kg/m\^2 and stable weight for the past 3 months * has no history of type 2 diabetes mellitus (t2dm) or a history of t2dm controlled by diet or stable doses of antihyperglycemic agents (ahas) * contraceptive use by male participants should be consistent with local regulations. * a female participant is eligible to participate if she is not pregnant or breastfeeding, and she is not a woman of child-bearing potential (wocbp) or she is a wocbp and uses a contraceptive method that is highly effective during the intervention period and for at least 16 weeks after the last dose of study intervention. exclusion criteria * has presence of cirrhosis on liver biopsy * has type 1 diabetes * has a history of malignancy, unless cancer free ≥5 years, or is under evaluation for active or suspected malignancy except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer * has a history of bariatric surgery ≤5 years before study participation * has undergone a major surgical procedure ≤3 months before study participation or has major surgery planned during the study * has a history or evidence of chronic liver disease other than nash. individuals with a history of hepatitis b or c may be eligible for participation. * has significant systemic or major illnesses other than liver disease, including recent events (≤6 months before study entry) of congestive heart failure, unstable coronary artery disease, arterial revascularization, pulmonary disease, renal failure, stroke, transient ischemic attack, or organ transplantation

Keywords: non-alcoholic fatty liver disease
comparative effectiveness of qigong exercise versus wu dang tai chi chuan in cvd risk individuals

Conditions: Cardiovascular Diseases; Risk Behavior, Health

Summary: to compare whether the qigong exercise or wu dang tai chi chuan will be effective in improving exercise capacity and reducing stress in cvd-risk individuals. based on preliminary data, qigong and tai-chi may help treat anxiety and depression symptoms in patients with chronic illnesses as well as in healthy adults. without the need for specialized equipment, qigong and tai-chi are both readily adjustable mind-body exercises that may be done whenever and wherever. for this reason, qigong and taichi should be extensively encouraged as ways to enhance emotional wellbeing

since no comparison study has thus far been carried out in pakistan which includes both interventions and very little literature is available. they belong to a group of chinese exercises known for their efficacy in reducing blood pressure, stress, and quality of life and improving exercise capacity in patients with a high risk of cvd or cvd disease. these techniques are cost-effective treatment approaches and provide early outcomes. the positive results of this study would be helpful in the near future.

Eligibility criteria:
inclusion criteria: * according to the framingham risk calculator 10% to 20%+ for moderate to high-risk * patients at risk of cvd (last 6 months) * patients with either htn, dyslipidemia, or diabetes * patients with less than 45 scores on the berg balance scale * stress from moderate to severe on pss * no regular physical exercise for at least 1 year * willing to take part exclusion criteria: * history of stroke * cvd * acute infection * acute injury * any diagnosed psychological issue * msk disorders * member of marital arts/dance

Keywords: qigong exercise wu dang tai chi chuan exercise capacity cvd risk individuals
effectiveness of virtual reality exercises in stroke rehabilitation (evrest)

Conditions: Stroke

Summary: this study is a pilot, randomized trial that will examine whether the nintendo wii virtual gaming system is safe and feasible for use in patients who have had a recent stroke.

a pilot, randomized (1:1) controlled trial to compare the safety and feasibility of nintendo wii gaming versus other recreational therapy activities (playing cards) in post-stroke patients. all patients will continue to receive all other standard medical and physiotherapy treatments while in the study.

Eligibility criteria:
inclusion criteria: * patient has provided written informed consent prior to entry into the study * in-patient at one of the two study institutions at the time of randomization * males or females, aged over 18 and younger than 85 * evidence of stroke confirmed by ct head (ischemic or hemorrhagic) * time: onset of symptoms within 6 months prior to randomization * measurable chedoke-mcmaster scale stage of =\>4 on the "arm" item (10) * functional independence prior to present stroke (baseline mrs = 0-1) * patient is alert, medically stable according to the treating physician and able to follow simple verbal commands exclusion criteria: * acute stroke onset more than 6 months ago * patient is unable to follow verbal commands or has global aphasia * severe illness with life expectancy less than 3 months (cancer, endocarditis, metastasis with an occult primary malignancy, coagulopathy). * uncontrolled hypertension according to the treating physician * unstable angina or recent myocardial infarction (within the last 3 months), current ny heart association class iii (marked limitation of physical activity; although patients are comfortable at rest, less-than-ordinary activity leads to fatigue, dyspnea, palpitations, or angina3) or iv (symptomatic at rest; symptoms of chf are present at rest; discomfort increases with any physical activity) or symptomatic ventricular tachyarrhythmias, as per medical history (a baseline ecg will not be required.) * any history of seizure, except for febrile seizures of childhood * participation in another clinical trial involving rehabilitation (recreational therapy, occupational therapy, physiotherapy) or involving an investigational drug. * patient is unwilling or unable to comply with the protocol or can not/will not cooperate fully with the investigator or study personnel. * any condition(s) that, in the investigator's opinion, would a) warrant exclusion from the study (i.e., participation in the study is not in the best interest of the patient) or b) prevent the patient from completing the study. * any medical condition that might confound the interpretation of results or put the patient at risk (amputation of one extremity).

Keywords: stroke rehabilitation nintendo wii
impact of body weight on outcomes of patients undergoing coronary artery bypass grafting

Conditions: Obesity; Coronary Artery Disease; Angina Pectoris; Coronary; Ischemic

Summary: all consecutive patients who underwent isolated coronary artery bypass grafting (cabg) at our institution from 2014 to 2020 were included. patients were divided into 6 groups according to body mass index (bmi): underweight (bmi \&lt;20.0 kg/m2), normal weight (bmi 20.0-24.9 kg/m2), overweight (bmi, 25-29.9 kg/m2), obesity class i (bmi 30-34.9 kg/m2), obesity class ii (bmi 35-39.9 kg/m2) and obesity class iii (bmi \&gt;40 kg/m2). the long-term mortality was analyzed as primary end-point. the univariable and multivariable analysis was performed using logistic regression modeling.

all consecutive patients aged above eighteen who underwent isolated cabg were enrolled. patients operated on- and off-pump were included. we reviewed elective, urgent, emergency and salvage surgeries. patients with any additional concomitant surgical procedures were excluded. patients were divided into 6 groups according to body mass index (bmi): underweight (bmi \&lt;20.0 kg/m2), normal weight (bmi 20.0-24.9 kg/m2), overweight (bmi, 25-29.9 kg/m2), obesity class i (bmi 30-34.9 kg/m2), obesity class ii (bmi 35-39.9 kg/m2) and obesity class iii (bmi \&gt;40 kg/m2). the primary endpoint was long-term mortality. the secondary end-point was the rate of sternal wound infections. summary statistics were calculated. continuous data are described as the median, with the interquartile range in parentheses, while categorical data are shown as numbers with percentages. differences between groups for normally distributed, continuous variables were determined using the one-way analysis of variance with holm-sidak post-hoc test. the kruskal wallis test was used for the analysis of non-normally distributed continuous variables with dunn's test for post hoc comparison. the chi-squared test was used for the analysis of categorical variables. bonferoni's correction was used for post-hoc analysis. the univariable analysis was performed using logistic regression. for multivariable analysis a logistic regression model was performed, with mortality or wound infection as the dependent variable, and all other characteristics summarized in the table 1 as independent variables. the backward conditional selection was used for modeling with variables with score statistics \&lt;0.1 included in the model. significance was assessed at p\&lt;0.05. multiple imputation was not used to adjust for missing data. the number of valid entries for each variable and alterations in the sample size for specific analyses are described. analyses were performed using ibm spss version 22.0 and medcalc version 19.4.1.

Eligibility criteria:
inclusion criteria: * patients undergoing isolated cabg exclusion criteria: any concomitant additional surgical procedures

Keywords: body mass index coronary artery bypass grafting obesity mortality
standard iv cannula aspiration (sivca): a novel, efficient and minimally invasive testicular sperm aspiration technique

Conditions: Non Obstructive Azoospermia

Summary: study question: can enough testicular tissue be aspirated for sperm retrieval in non-obstructive azoospermia (noa), using a wide bore 14-g standard iv cannula in comparison to micro-tese? summary answer: standard iv cannula aspiration (sivca) can yield an ample amount of testicular tissue sufficient for sperm retrieval through a single puncture site on the scrotum.

what is known already: the current conventional method of testicular sperm aspiration is fine needle aspiration (fna). fna has the advantage of being a cost-effective and minimally invasive procedure compared to open testicular sperm extraction (tese). but fna with its conventional 23-g needle may not always yield enough testicular tissue for sperm retrieval. furthermore, fna may require multiple punctures on the scrotum to retrieve enough tissues from different areas of the testis. study design, size, duration: a 24 months prospective cohort study conducted at a specialized ivf center. a total of 130 men aged from 22 to 53 years old (35.03 +/- 9.04) with noa and normal testicular volume (≥ 12ml) were enrolled in the study. the men had testicular biopsies taken at the day of their partners' ovum pick-up. on each patient, the testes were randomized to undergo sivca on one testis followed by micro-tese on the contralateral testis. participants/materials, setting, methods: after local anesthesia, a wide bore 14-g standard iv cannula was introduced near the lower pole of the testis. the needle was withdrawn and the catheter introduced into the testicular tissue. a 20-ml syringe was secured to the catheter and constant negative pressure applied and secured with a clamp. back and forth motions were performed covering as many areas of the testis as possible. micro-tese was then performed on the contralateral testis.sperm retrieval rates (srr) will be compared between the two techniques using mcnemar χ2 test. a p-value of less than 0.05 was considered to be statistically significant.

Eligibility criteria:
inclusion criteria: * non obstructive azoospermia * normal sized testes (above 12ml in volume) exclusion criteria: * obstructive azoospermia * small sized testes

Keywords: non obstructive azoospermia fine needle aspiration micro-tese
an open label access study for subjects who completed a1481156

Conditions: Pulmonary Arterial Hypertension

Summary: the purpose of this study is to provide sildenafil therapy to subjects who have completed the a1481156 study for the treatment of pulmonary arterial hypertension (pah) in india and are judged by the investigator to derive clinical benefit from continued treatment with sildenafil citrate. sildenafil citrate will be supplied for the treatment of pulmonary arterial hypertension (pah) until the subject continues to derive benefits from the treatment. the treating physicians (and the sponsor) will be responsible for reporting serious adverse events.


Eligibility criteria:
inclusion criteria: * subjects who have completed study a1481156 and are judged by the investigator to derive clinical benefit from continuous treatment with sildenafil citrate therapy. * subjects with pulmonary arterial hypertension (pah ) being treated at a study site in india * subjects who are willing and able to comply with scheduled visits, treatment plan, and other study procedures exclusion criteria: * pregnant or lactating female subjects. * current participation in other studies and during study participation, except for the a1481304 follow-up period. * other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
the effect of inspiratory muscle training with substance use disorder

Conditions: Substance Abuse Disorder; Exercise; Pulmonary Function; Rehabilitation

Summary: the aim was to investigate the effectiveness of inspiratory muscle training on dyspnoea, pulmonary function, respiratory muscle strength, cough capacity, functional exercise capacity, substance craving, depression, anxiety and quality of life in individuals with substance use disorder.

in recent years, substance use has increased among young people in our country, and studies investigating the negative effects of substances on pulmonary health have also increased. it has been emphasized in the literature that the most appropriate features should be determined for the exercise program in the treatment of individuals with sud. although studies in the literature have reported that substance use affects respiratory functions and creates a restrictive or obstructive pattern, no study investigating the effects of inspiratory muscle training has been found in the literature. to our knowledge, this study is the first to examine the effects of inspiratory muscle training on respiratory function in individuals with sud. in our study, it was assumed that inspiratory muscle training could be a simple and inexpensive technique to improve dyspnea, respiratory functions, respiratory muscle strength, cough capacity, and exercise capacity in individuals with sud, reduce substance cravings, increase quality of life, and reduce depression and anxiety, thus making it suitable for routine clinical use. the aim was to examine the effectiveness of inspiratory muscle training on dyspnea, respiratory functions, respiratory muscle strength, functional exercise capacity, substance craving, anxiety, depression, and quality of life in individuals with substance use disorders.

Eligibility criteria:
inclusion criteria: * being older than 18 years * meeting the current diagnostic and statistical manual of mental disorders, 5th edition (dsm-5) criteria for substance use disorder * receiving inpatient treatment * substance use for more than one year * being able to follow simple instructions * not having any visual and auditory pathology * being able to cooperate with the devices used. exclusion criteria: * failure to comply with the treatment and assessment program * participation in a structured physiotherapy/exercise program in the last 6 months * presence of current psychotic symptoms * presence of any physical disability or medical problem * presence of respiratory system problems such as asthma and tuberculosis and infectious health problems (e.g. hiv, hepatitis b).

Keywords: substance use disorder exercise rehabilitation pulmonary function muscle training